Dyne Therapeutics annual diluted eps
Diluted EPSBasic EPS
2019
2020
2021
2022
2023
2024
2025
Dyne Therapeutics EPS History: Annual & Quarterly (DYN)
Dyne Therapeutics's diluted EPS was -$3.47 for fiscal 2025.
View full Dyne Therapeutics company overviewDyne Therapeutics annual diluted eps history
| Fiscal year | Period ended | Diluted EPS | Basic EPS | Change | Growth |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | -$3.47 | -$3.47 | -$0.10 | — |
| 2024 | 2024-12-31 | -$3.37 | -$3.37 | $0.58 | — |
| 2023 | 2023-12-31 | -$3.95 | -$3.95 | -$0.72 | — |
| 2022 | 2022-12-31 | -$3.23 | -$3.23 | -$0.30 | — |
| 2021 | 2021-12-31 | -$2.93 | -$2.93 | $1.20 | — |
| 2020 | 2020-12-31 | -$4.13 | -$4.13 | $1.95 | — |
| 2019 | 2019-12-31 | -$6.08 | -$6.08 | — | — |
Dyne Therapeutics quarterly diluted eps
Diluted EPSBasic EPS
Q3.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Diluted EPS | Basic EPS | Change | YoY change |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | -$1.08 | -$1.08 | -$0.11 | — |
| Q1 2026 | 2026-03-31 | -$0.73 | -$0.73 | $0.32 | — |
| Q4 2025 | 2025-12-31 | -$0.76 | -$0.76 | — | — |
| Q3 2025 | 2025-09-30 | -$0.76 | -$0.76 | $0.20 | — |
| Q2 2025 | 2025-06-30 | -$0.97 | -$0.97 | -$0.27 | — |
| Q1 2025 | 2025-03-31 | -$1.05 | -$1.05 | -$0.24 | — |
| Q3 2024 | 2024-09-30 | -$0.96 | -$0.96 | $0.03 | — |
| Q2 2024 | 2024-06-30 | -$0.70 | -$0.70 | $0.38 | — |
| Q1 2024 | 2024-03-31 | -$0.81 | -$0.81 | -$0.03 | — |
| Q3 2023 | 2023-09-30 | -$0.99 | -$0.99 | -$0.19 | — |
| Q2 2023 | 2023-06-30 | -$1.08 | -$1.08 | -$0.07 | — |
| Q1 2023 | 2023-03-31 | -$0.78 | -$0.78 | -$0.09 | — |
| Q3 2022 | 2022-09-30 | -$0.80 | -$0.80 | $0.03 | — |
| Q2 2022 | 2022-06-30 | -$1.01 | -$1.01 | -$0.43 | — |
| Q1 2022 | 2022-03-31 | -$0.69 | -$0.69 | -$0.19 | — |
| Q3 2021 | 2021-09-30 | -$0.83 | -$0.83 | $1.18 | — |
| Q2 2021 | 2021-06-30 | -$0.58 | -$0.58 | $2.73 | — |
| Q1 2021 | 2021-03-31 | -$0.50 | -$0.50 | $0.40 | — |
| Q3 2020 | 2020-09-30 | -$2.01 | -$2.01 | $0.35 | — |
| Q2 2020 | 2020-06-30 | -$3.31 | -$3.31 | — | — |
| Q1 2020 | 2020-03-31 | -$0.90 | -$0.90 | — | — |
| Q3 2019 | 2019-09-30 | -$2.36 | -$2.36 | — | — |
Dyne Therapeutics diluted eps trends
Over the last five fiscal years, Dyne Therapeutics's diluted eps increased from -$4.13 to -$3.47, a change of $0.66. The latest reported quarter, Q2 2026, shows -$1.08.
About the metric
What earnings per share (EPS) means
Earnings per share (EPS) shows how much profit or loss is attributable to each common share. Diluted EPS includes the potential effect of convertible securities, options, and other instruments that could increase the share count, while basic EPS uses the weighted-average common shares actually outstanding.
Calculation and source
SEC-reported diluted and basic EPS
TickerStat displays diluted and basic earnings per share from SEC filings. Historical EPS values are adjusted to the current share basis when SEC-reported stock-split conversion ratios are available; they are not analyst estimates or earnings forecasts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Dyne Therapeutics source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...